Research Topics
| Michael T MilanoSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Normal tissue tolerance dose metrics for radiation therapy of major organsMichael T Milano
Department of Radiation Oncology and James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Semin Radiat Oncol 17:131-40. 2007..This review summarizes the published clinical data on the risk of late toxicity as a function of quantitative dose metrics and attempts to offer suggested dose constraints for radiation treatment planning...
Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patientsMichael T Milano
Department of Radiation Oncology and Rubin Center for Cancer Survivorship, University of Rochester School of Medicine, Rochester, New York 14642, USA
Cancer 117:5538-47. 2011..However, no population-based studies have compared overall survival (OS) between HL survivors who developed nonsmall cell lung cancer (HL-NSCLC) versus patients with first primary NSCLC (NSCLC-1)...
Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based studyMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
J Clin Oncol 28:5088-96. 2010..However, there are no large population-based studies that describe overall survival (OS) and cause-specific survival (CSS) compared with women with first primary BC...- Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous systemMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Cancer Treat Rev 37:567-78. 2011..The impact of dose, volume, fractionation, and other relevant clinic-pathologic variables are discussed, as are limitations of the published data... - Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective studyMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Radiat Oncol Biol Phys 83:878-86. 2012..To analyze the long-term survival and tumor control outcomes after stereotactic body radiotherapy (SBRT) for metastases limited in number and extent... - Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapyMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
Int J Radiat Oncol Biol Phys 72:1516-22. 2008..To characterize oligometastases in patients enrolled on two prospective pilot studies, treating oligometastases with hypofractionated stereotactic body radiotherapy and stereotactic radiosurgery to cranial lesions... - Central thoracic lesions treated with hypofractionated stereotactic body radiotherapyMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Radiother Oncol 91:301-6. 2009..To investigate the toxicity and outcome after moderately hypofractionated stereotactic body radiotherapy (SBRT) for central thoracic lesions... - Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapyMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, P O Box 647, Rochester, NY 14642, USA
Breast Cancer Res Treat 115:601-8. 2009..Prospective pilot study to assess patient outcome after stereotactic body radiation therapy (SBRT) for limited metastases from breast cancer... - Split-course palliative radiotherapy for advanced non-small cell lung cancerSu K Metcalfe
Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
J Thorac Oncol 5:185-90. 2010..Albeit an important subject, there is a lack of consensus for an optimal palliative RT regimen. We report the outcomes of a split-course palliative chest RT, a frequently used schema at our institution... - Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancerPraveena Cheruvu
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York, USA
Radiat Oncol 6:80. 2011..We hypothesized that patients treated with SBRT for limited metastases have comparable outcomes with those treated with curative-intent radiation for Stage III NSCLC... - Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastomaMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Radiat Oncol Biol Phys 78:1147-55. 2010..To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation... - Primary spinal cord glioma: a Surveillance, Epidemiology, and End Results database studyMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, Box 647, Rochester, NY 14642, USA
J Neurooncol 98:83-92. 2010..Given the retrospective nature of this study, specific recommendations about which situations warrant radiotherapy cannot be determined... - Definitive radiotherapy for stage I nonsmall cell lung cancer: a population-based study of survivalMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
Cancer 118:5572-9. 2012.... - Spurious progression in pediatric brain tumorsSheema Chawla
Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave Box 647, Rochester, NY 14642, USA
J Neurooncol 107:651-7. 2012..Therefore, SP occurs more commonly in children with low grade tumors, but can also occur with high grade brain tumors, regardless of therapeutic approach... - Patterns of recurrence after curative-intent radiation for oligometastases confined to one organMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
Am J Clin Oncol 33:157-63. 2010.... - Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastomaRajiv Mangla
Department of Imaging Sciences, University of Rochester Medical Center, 601 Elmwood Ave, PO Box 648, Rochester, NY 14642 8648, USA
Radiology 256:575-84. 2010.... - Normal tissue toxicity after small field hypofractionated stereotactic body radiationMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Radiat Oncol 3:36. 2008..While clinical data has shown SBRT to be safe in most circumstances, more data is needed to refine the ideal dose-volume metrics... - Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy coursesMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Radiat Oncol Biol Phys 73:832-7. 2009..We hypothesized that these patients would remain amenable to curative-intent treatment with additional RT courses... - Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlationAlan W Katz
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Radiat Oncol Biol Phys 83:895-900. 2012..We also examined histological response to radiation in the resected or explanted livers... - Impact of radiotherapy on laryngeal cancer survival: a population-based study of 13,808 US patientsHong Zhang
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642 8647, USA
Cancer 118:1276-87. 2012..However, the impact of radiation on overall survival (OS) in a large population-based study has not been evaluated to date... - Stereotactic Body Radiation Therapy (SBRT) for lung metastasesPaul Okunieff
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
Acta Oncol 45:808-17. 2006..Median survival time and progression-free survival both appear better than that achieved with standard care alone. Long-term progression-free survival can be seen in a subset of patients when all tumors are targeted... - Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survivalSughosh Dhakal
Department of Radiation Oncology, University of Rochester, Rochester, NY, USA
Int J Radiat Oncol Biol Phys 82:940-5. 2012..Since 2001, we have treated PM with stereotactic body radiation therapy (SBRT). We postulated that SBRT for PM from STS would yield excellent local control (LC) and overall survival (OS)... - Stereotactic body radiotherapy for treatment of adrenal metastasesSheema Chawla
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Radiat Oncol Biol Phys 75:71-5. 2009..To investigate the dosimetry and outcomes of patients undergoing stereotactic body radiotherapy (SBRT) for metastases to the adrenal glands... - A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesionsMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
Cancer 112:650-8. 2008..It is hypothesized that oligometastatic disease represents a state of potentially curable, limited metastases. Stereotactic body radiation therapy (SBRT) is an option for patients who are not amenable to or do not want resection... - Stereotactic radiosurgery for spinal metastases: case report and review of treatment optionsSheema Chawla
University of Rochester Medical Center, Department of Radiation Oncology, 601 Elmwood Ave Box 647, Rochester, NY 14642, USA
Bone 45:817-21. 2009..We also review the literature on treatment of spinal metastases using SRS, SBRT, and other modalities... - Incidental brain lesions in children: to treat or not to treat?Amy Lee Bredlau
University of Rochester, Rochester, NY 14642, USA
J Neurooncol 106:589-94. 2012..The outcome for children with such lesions is excellent. Close monitoring of these patients with serial MRIs may be a safe alternative to immediate biopsy and/or resection for select patients... - Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastasesAlan W Katz
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Radiat Oncol Biol Phys 67:793-8. 2007..To evaluate the feasibility and efficacy of hypofractionated stereotactic body radiation therapy (SBRT) for the treatment of liver metastases... - Malignant pleural mesothelioma: a population-based study of survivalMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
J Thorac Oncol 5:1841-8. 2010..This study characterizes the overall survival (OS) and variables affecting OS in patients with malignant pleural mesothelioma... - Second course of radiation for new primary head-and-neck cancer: population-based study of survivalMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, NY, USA
Am J Clin Oncol 34:367-71. 2011..To analyze patient and tumor characteristics, and survival of patients who received 2 courses of radiotherapy for different primary head and neck cancers (HNCs)... - Stereotactic radiosurgery for glioblastoma: retrospective analysisTithi Biswas
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Radiat Oncol 4:11. 2009..This retrospective study was done to better understand the conditions for which stereotactic radiosurgery (SRS) for glioblastoma may be efficacious... - New prospects for management and treatment of inoperable and recurrent skull base meningiomasMahlon D Johnson
Department of Pathology and Laboratory Medicine, Division of Neuropathology, University of Rochester Medical Center, 601 Elmwood Ave Box 626, Rochester, NY 14623, USA
J Neurooncol 86:109-22. 2008..This article reviews some recent findings pathways that appear to regulate meningioma growth. Potential targets for novel therapies are also discussed... - Second primary lung cancer after head and neck squamous cell cancer: Population-based study of risk factorsMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642
Head Neck 34:1782-8. 2012..Patients with head and neck squamous cell cancer (HNSCC) are at risk of developing second primary lung cancer (SPLC)... - Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patientsMichael T Milano
Department of Radiation Oncology and Rubin Center for Cancer Survivorship, University of Rochester School of Medicine, Rochester, NY 14642, USA
J Thorac Dis 4:22-9. 2012..To date, no population-based study has analyzed prognostic variables for overall survival (OS) among HL survivors who developed non-small cell lung cancer (NSCLC)... - Thoracic malignant solitary fibrous tumors: A population-based study of survivalMichael T Milano
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
J Thorac Dis 3:99-104. 2011..This study characterizes the overall survival (OS) and cause specific survival (CSS) of patients with thoracic malignant solitary fibrous tumors... - Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinomaJoseph K Salama
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637-1470, USA
Int J Radiat Oncol Biol Phys 64:382-91. 2006..Owing to the substantial toxicity and lack of an optimal regimen, reirradiation of recurrent head-and-neck cancer should be limited to clinical trials... - Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directionsMichael T Milano
Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
Int J Oncol 28:1141-51. 2006..Building on the present clinical experience, future directions include more directed efforts at reducing toxicity, with better planning software and planning techniques... - Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcomeMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 59:445-53. 2004..To assess the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) in pancreatic and bile duct (cholangiocarcinoma) malignancies... - Intensity-modulated radiotherapy and the InternetDavid A Schomas
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637, USA
Cancer 101:412-20. 2004..26). CONCLUSIONS: In general, the content and quality of patient-oriented information regarding IMRT on the Internet were poor. Patients and their physicians need to be aware of these problems when selecting treatment courses... - Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcomeMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 63:354-61. 2005..Compared with historical controls, local control is not compromised despite efforts to increase conformality and reduce normal structure dose... - Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapyMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 61:1096-106. 2005..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck... - Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicityAshesh B Jani
Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637, USA
Urology 67:147-51. 2006..To provide a single-institution analysis of the influence of pelvic intensity-modulated radiotherapy (RT) on acute genitourinary (GU) and gastrointestinal (GI) toxicity... - Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancerJoseph K Salama
Departments of Radiation and Cellular Oncology, University of Chicago, 5758 S. Maryland Avenue, Chicago, IL 60637-1470, USA
Cancer J 11:140-6. 2005..DISCUSSION: The maximum tolerated dose and recommended phase II dose of CPT-11 with hyperfractionated radiation therapy is 10 mg/m(2)/d...